Analytical Data
-
基因名
LAG3
- Application
-
别名
LAG3；FDC；Lymphocyte activation gene 3 Protein
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P18627
-
表达区间
23-450aa
-
氨基酸序列
LQPGAEVPVV WAQEGAPAQL PCSPTIPLQD LSLLRRAGVT WQHQPDSGPP AAAPGHPLAP GPHPAAPSSW GPRPRRYTVL SVGPGGLRSG RLPLQPRVQL DERGRQRGDF SLWLRPARRA DAGEYRAAVH LRDRALSCRL RLRLGQASMT ASPPGSLRAS DWVILNCSFS RPDRPASVHW FRNRGQGRVP VRESPHHHLA ESFLFLPQVS PMDSGPWGCI LTYRDGFNVS IMYNLTVLGL EPPTPLTVYA GAGSRVGLPC RLPAGVGTRS FLTAKWTPPG GGPDLLVTGD NGDFTLRLED VSQAQAGTYT CHIHLQEQQL NATVTLAIIT VTPKSFGSPG SLGKLLCEVT PVSGQERFVW SSLDTPSQRS FSGPWLEAQE AQLLSQPWQC QLYQGERLLG AAVYFTELSS PGAQRSGRAP GALPAGHL
-
分子量
48 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LAG3, or Lymphocyte Activation Gene 3, is an immune checkpoint receptor that plays a crucial role in regulating T cell activity and maintaining immune tolerance. Its significance in immunotherapy, particularly in the context of cancer treatment, has garnered increasing interest from researchers. Unlike PD-1 and CTLA-4, LAG3 can inhibit not only T cell activation but also the proliferation and function of various immune cells. This unique mechanism positions LAG3 as a potential target for therapeutic interventions aimed at enhancing anti-tumor immunity. The development of LAG3-based fusion proteins or monoclonal antibodies has shown promising results in preclinical models and early-phase clinical trials, suggesting that modulation of LAG3 could improve the efficacy of existing cancer therapies. Additionally, understanding the structural biology and interactions of LAG3 with its ligands can inform the design of innovative agents that could synergistically enhance immune responses. Overall, research into LAG3 and its recombinant proteins is critical for advancing the field of immunotherapy and developing strategies to overcome resistance in cancer treatment.
